GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Tianjin Pharmaceutical Da Ren Tang Group Corp Ltd (SHSE:600329) » Definitions » Equity-to-Asset

Tianjin Pharmaceutical Da Ren Tang Group (SHSE:600329) Equity-to-Asset : 0.63 (As of Mar. 2024)


View and export this data going back to 2001. Start your Free Trial

What is Tianjin Pharmaceutical Da Ren Tang Group Equity-to-Asset?

Equity to Asset ratio is calculated as total stockholders equity divided by total asset. Tianjin Pharmaceutical Da Ren Tang Group's Total Stockholders Equity for the quarter that ended in Mar. 2024 was ¥6,987 Mil. Tianjin Pharmaceutical Da Ren Tang Group's Total Assets for the quarter that ended in Mar. 2024 was ¥11,051 Mil. Therefore, Tianjin Pharmaceutical Da Ren Tang Group's Equity to Asset Ratio for the quarter that ended in Mar. 2024 was 0.63.

The historical rank and industry rank for Tianjin Pharmaceutical Da Ren Tang Group's Equity-to-Asset or its related term are showing as below:

SHSE:600329' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.49   Med: 0.67   Max: 0.71
Current: 0.63

During the past 13 years, the highest Equity to Asset Ratio of Tianjin Pharmaceutical Da Ren Tang Group was 0.71. The lowest was 0.49. And the median was 0.67.

SHSE:600329's Equity-to-Asset is ranked better than
57.79% of 1085 companies
in the Drug Manufacturers industry
Industry Median: 0.59 vs SHSE:600329: 0.63

Tianjin Pharmaceutical Da Ren Tang Group Equity-to-Asset Historical Data

The historical data trend for Tianjin Pharmaceutical Da Ren Tang Group's Equity-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Tianjin Pharmaceutical Da Ren Tang Group Equity-to-Asset Chart

Tianjin Pharmaceutical Da Ren Tang Group Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Equity-to-Asset
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.69 0.70 0.70 0.64 0.65

Tianjin Pharmaceutical Da Ren Tang Group Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Equity-to-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.64 0.61 0.63 0.65 0.63

Competitive Comparison of Tianjin Pharmaceutical Da Ren Tang Group's Equity-to-Asset

For the Drug Manufacturers - Specialty & Generic subindustry, Tianjin Pharmaceutical Da Ren Tang Group's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Tianjin Pharmaceutical Da Ren Tang Group's Equity-to-Asset Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Tianjin Pharmaceutical Da Ren Tang Group's Equity-to-Asset distribution charts can be found below:

* The bar in red indicates where Tianjin Pharmaceutical Da Ren Tang Group's Equity-to-Asset falls into.



Tianjin Pharmaceutical Da Ren Tang Group Equity-to-Asset Calculation

Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.

Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.

Tianjin Pharmaceutical Da Ren Tang Group's Equity to Asset Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Equity to Asset (A: Dec. 2023 )=Total Stockholders Equity/Total Assets
=6600.691/10230.101
=0.65

Tianjin Pharmaceutical Da Ren Tang Group's Equity to Asset Ratio for the quarter that ended in Mar. 2024 is calculated as

Equity to Asset (Q: Mar. 2024 )=Total Stockholders Equity/Total Assets
=6987.126/11050.623
=0.63

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Tianjin Pharmaceutical Da Ren Tang Group  (SHSE:600329) Equity-to-Asset Explanation

Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.

For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.


Tianjin Pharmaceutical Da Ren Tang Group Equity-to-Asset Related Terms

Thank you for viewing the detailed overview of Tianjin Pharmaceutical Da Ren Tang Group's Equity-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.


Tianjin Pharmaceutical Da Ren Tang Group (SHSE:600329) Business Description

Traded in Other Exchanges
Address
No. 17 Baidi Road, Zhong Xin Mansion, Nankai District, Tianjin, CHN, 300193
Tianjin Pharmaceutical Da Ren Tang Group Corp Ltd is a pharmaceutical manufacturing company. The company manufactures and sells traditional Chinese medicine, western medicine, and healthcare products in the People's Republic of China. It operates in two segments namely The Chinese Medicine segment and The Western Medicine segment. The Chinese Medicine segment manufactures Chinese pharmaceutical products under brands owned by the group. The Western Medicine segment manufactures western pharmaceutical products through cooperation with foreign companies. The company earns the majority of its revenue from the sale of Chinese pharmaceutical products.

Tianjin Pharmaceutical Da Ren Tang Group (SHSE:600329) Headlines

No Headlines